TY - JOUR
T1 - Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation
T2 - I-MOVECOVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022
AU - Rose, Angela Mc
AU - Nicolay, Nathalie
AU - Sandonis Martín, Virginia
AU - Mazagatos, Clara
AU - Petrović, Goranka
AU - Baruch, Joaquin
AU - Denayer, Sarah
AU - Seyler, Lucie
AU - Domegan, Lisa
AU - Launay, Odile
AU - Machado, Ausenda
AU - Burgui, Cristina
AU - Vaikutyte, Roberta
AU - Niessen, F. Annabel
AU - Loghin, Isabela I.
AU - Husa, Petr
AU - Aouali, Nassera
AU - Panagiotakopoulos, George
AU - Tolksdorf, Kristin
AU - Horváth, Judit Krisztina
AU - Howard, Jennifer
AU - Pozo, Francisco
AU - Gallardo, Virtudes
AU - Nonković, Diana
AU - Džiugytė, Aušra
AU - Bossuyt, Nathalie
AU - Demuyser, Thomas
AU - Duffy, Róisín
AU - Luong Nguyen, Liem Binh
AU - Kislaya, Irina
AU - Martínez-Baz, Iván
AU - Gefenaite, Giedre
AU - Knol, Mirjam J.
AU - Popescu, Corneliu
AU - Součková, Lenka
AU - Simon, Marc
AU - Michelaki, Stella
AU - Reiche, Janine
AU - Ferenczi, Annamária
AU - Delgado-Sanz, Concepción
AU - Lovrić Makarić, Zvjezdana
AU - Cauchi, John Paul
AU - Barbezange, Cyril
AU - Van Nedervelde, Els
AU - O'Donnell, Joan
AU - Durier, Christine
AU - Guiomar, Raquel
AU - Castilla, Jesús
AU - Jonikaite, Indrė
AU - Bruijning-Verhagen, Patricia Cjl
AU - I-MOVE-COVID-19 hospital study team
AU - VEBIS hospital study team
AU - Members of the I-MOVE-COVID-19 and VEBIS hospital study teams (in addition to authors above)
N1 - Acknowledgements
Study teams are very grateful to all patients, physicians, laboratory teams, and national or regional epidemiologists who have contributed to the study.
The Spanish team thanks all the participants in the SiVIRA Group for Surveillance and vaccine effectiveness in Spain), including everyone involved in data collection and notification at the sentinel hospitals, laboratories, and public health units of all participating Autonomous Regions. The Romanian study team in addition thanks Elena Duca, George Silvas, Adriana Bahna, Oana Secrieru (Spitalul Clinic de Boli Infectioase “Sfanta Parascheva”) and Alma Gabriela Kosa, Daniel Codreanu, Gratiela Tardei (Spitalul Clinic de Boli Infectioase si Tropicale dr Victor Babes) for their hard work. The Hungarian study team works as part of the National Laboratory for Health Security Hungary (RRF-2.3.1-21-2022-00006) supported by the National Research, Development and Innovation Office (NKFIH).
Participating laboratories submitted their sequences to GISAID (www.gisaid.org) for easy sharing with the central laboratory in Madrid.
PY - 2023/11/23
Y1 - 2023/11/23
N2 - Introduction: The I-MOVE-COVID-19 and VEBIS hospital networks have been measuring COVID-19 vaccine effectiveness (VE) in participating European countries since early 2021. Aim: We aimed to measure VE against PCR-confirmed SARS-CoV-2 in patients ≥20 years hospitalised with severe acute respiratory infection (SARI) from December 2021 to July 2022 (Omicron-dominant period). Methods: In both networks, 46 hospitals (13 countries) follow a similar test-negative case–control protocol. We defined complete primary series vaccination (PSV) and first booster dose vaccination as last dose of either vaccine received≥14 days before symptom onset (stratifying first booster into received<150 and≥150 days after last PSV dose). We measured VE overall, by vaccine category/product, age group and time since first mRNA booster dose, adjusting by site as a fixed effect, and by swab date, age, sex, and presence/absence of at least one commonly collected chronic condition. Results: We included 2,779 cases and 2,362 controls. The VE of all vaccine products combined against hospitalisation for laboratory-confirmed SARS-CoV-2 was 43% (95% CI: 29–54) for complete PSV (with last dose received≥150 days before onset), while it was 59% (95% CI: 51–66) after addition of one booster dose. The VE was 85% (95% CI: 78–89), 70% (95% CI: 61–77) and 36% (95% CI: 17–51) for those with onset 14–59 days, 60–119 days and 120–179 days after booster vaccination, respectively. Conclusions: Our results suggest that, during the Omicron period, observed VE against SARI hospitalisation improved with first mRNA booster dose, particularly for those having symptom onset<120 days after first booster dose.
AB - Introduction: The I-MOVE-COVID-19 and VEBIS hospital networks have been measuring COVID-19 vaccine effectiveness (VE) in participating European countries since early 2021. Aim: We aimed to measure VE against PCR-confirmed SARS-CoV-2 in patients ≥20 years hospitalised with severe acute respiratory infection (SARI) from December 2021 to July 2022 (Omicron-dominant period). Methods: In both networks, 46 hospitals (13 countries) follow a similar test-negative case–control protocol. We defined complete primary series vaccination (PSV) and first booster dose vaccination as last dose of either vaccine received≥14 days before symptom onset (stratifying first booster into received<150 and≥150 days after last PSV dose). We measured VE overall, by vaccine category/product, age group and time since first mRNA booster dose, adjusting by site as a fixed effect, and by swab date, age, sex, and presence/absence of at least one commonly collected chronic condition. Results: We included 2,779 cases and 2,362 controls. The VE of all vaccine products combined against hospitalisation for laboratory-confirmed SARS-CoV-2 was 43% (95% CI: 29–54) for complete PSV (with last dose received≥150 days before onset), while it was 59% (95% CI: 51–66) after addition of one booster dose. The VE was 85% (95% CI: 78–89), 70% (95% CI: 61–77) and 36% (95% CI: 17–51) for those with onset 14–59 days, 60–119 days and 120–179 days after booster vaccination, respectively. Conclusions: Our results suggest that, during the Omicron period, observed VE against SARI hospitalisation improved with first mRNA booster dose, particularly for those having symptom onset<120 days after first booster dose.
KW - COVID-19
KW - Europe
KW - hospital
KW - omicron
KW - SARS-CoV-2
KW - vaccine effectiveness
UR - http://www.scopus.com/inward/record.url?scp=85177865991&partnerID=8YFLogxK
UR - https://pubmed.ncbi.nlm.nih.gov/37997665
U2 - 10.2807/1560-7917.ES.2023.28.47.2300187
DO - 10.2807/1560-7917.ES.2023.28.47.2300187
M3 - Article
C2 - 37997665
AN - SCOPUS:85177865991
SN - 1025-496X
VL - 28
JO - Eurosurveillance
JF - Eurosurveillance
IS - 47
M1 - 2300187
ER -